Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ipsen Sa ADR (OP:IPSEY)

44.63 +0.04 (+0.10%)
Streaming Delayed Price Updated: 10:01 AM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ipsen Sa ADR

< Previous 1 2 Next >
News headline image
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
Via Talk Markets
Topics Initial Public Offering
News headline image
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo ↗
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
Via Benzinga
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
News headline image
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
Via Benzinga
News headline image
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases ↗
 
Via Benzinga
News headline image
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients ↗
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)  
Via Benzinga
News headline image
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga
News headline image
Why These Two Biotech Stocks Blasted Higher This Week ↗
There's nothing like a big-premium buyout to send a company's share price to the moon. 
Via The Motley Fool
News headline image
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday ↗
The market is moving higher, and these small companies are helping. 
Via The Motley Fool
News headline image
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗
 
Via Benzinga
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
News headline image
Why Merrimack Shares Are Surging Over 200% Today? ↗
 
Via Benzinga
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
News headline image
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure ↗
 
Via Benzinga
News headline image
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why ↗
Ipsen SA (OTC: IPSEY) has 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer ↗
 
Via Benzinga
News headline image
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer ↗
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have  
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
News headline image
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease ↗
Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... 
Via Benzinga
News headline image
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters ↗
Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful ↗
Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... 
Via Benzinga
News headline image
Ipsen Stock Declines After Pulling Rare Disease Application ↗
Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.